MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2025.12.009

Медицинская библиотека · Transplantation and cellular therapy · 2025

Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients.

Karapetyan Lilit, Kuriakose Joel, DiMaggio Elizabeth, Ward Kimberly, Chau Jamie, Otteni Christopher, Kalos Denise, Ali Johannes, Hall MacLean S, Beatty Matthew, Klinkova Olga V, Alomar Mohammed E, Gaskill Eric E, Gonzalez Rebecca M, Bailey Hanna, Yu Michael, Tran Nam, Rodriguez-Alfonso Lianicet, Vieira Ella, Adams Karla, Jain Michael, Locke Frederick L, Baldonado Jobelle, Perez Matthew C, Mullinax John, Zager Jonathan S, Gonzalez Ricardo, Sondak Vernon K, Markowitz Joseph, Brohl Andrew S, Eroglu Zeynep, Tarhini Ahmad A, Khushalani Nikhil I, Mulé James J, Sarnaik Amod A, Pilon-Thomas Shari

СтатьяПеревод в очереди

Аннотация

Nonmyeloablative lymphodepleting chemotherapy (LDC) is a crucial component of tumor-infiltrating lymphocyte (TIL) therapy ensuring T cell engraftment and durable antitumor activity. High-intensity preconditioning with cyclophosphamide (Cy; 60 mg/kg/day for 2 days) and fludarabine (Flu; 25 mg/m2/day for 5 days) dosing is typically used. Given the toxicity related to LDC, we investigated the safety and efficacy of reduced-dose LDC followed by standard of care lifileucel and high-dose interleukin-2 (IL-2) in a select cohort of melanoma patients. Patients received reduced-dose LDC if they met one or more of the following inclusion criteria: age ≥70 years, recently treated brain metastases, bowel metastases, bleeding, or need for continuous antiplatelet or anticoagulation use. LDC was given as Cy 30 mg/kg/day for 2 days and Flu 25 mg/ m2/day for 5 days, followed by a lifileucel infusion on day 0 and IL-2 (maximum 6 doses). Safety was evaluated using CTCAE v5, and efficacy was reported using RECIST v1.1. We treated 17 patients, including 9 males (53%) and 8 females (47%) The median patient age was 66 years (range, 36 to 78 years). Five had been treated for brain metastases, 59% had a lactate dehydrogenase level ≥ upper limit of normal, and 35% had a BRAFv600 mutation. The median number of IL-2 doses administered was 5 (range, 1 to 6). IL-2 was discontinued owing to patient refusal (n = 1), hypotension requiring vasopressor therapy (n = 1), grade 4 hyponatremia (n = 1), infection (n = 1), atrial fibrillation (n = 1), tachycardia (n = 1), grade 3 transaminitis (n = 2), and a combination of tachycardia and/or weight gain, hypoxia, and rigors (n = 3). All patients achieved grade 4 lymphopenia with a median absolute lymphocyte count nadir of 0.005 k/µL. The most frequent grade ≥3 treatment-related adverse events were anemia (n = 12; 71%), thrombocytopenia (n = 8; 47%), and febrile neutropenia (n = 10; 59%), with a median absolute neutrophil count recovery of 7 days. No deaths occurred within 30 days of TIL infusion. Among 16 evaluable patients, the best response was partial response in 7 patients (44%), stable disease in 3 (18%), and progressive disease in 6 (38%). The median follow-up was 10 months (95% confidence interval [CI], 8.7 months to not reached [NR]), the median duration of response was NR, the median progression-free survival was 5.1 months (95% CI, 4.3 to NR), and the median overall survival was NR (95% CI, 10 months to NR). Our data indicate that reducing Cy allowed successful completion of TIL therapy in high-risk metastatic melanoma patients without an obvious detrimental effect on response rate. This is the first report demonstrating the safety and feasibility of using real-world objective risk stratification to deliver reduced-dose lymphodepletion prior to lifileucel infusion in high-risk patients with metastatic melanoma. These findings warrant further investigation in a prospective trial of high-risk patients with metastatic melanoma.

Для цитирования: Karapetyan Lilit, Kuriakose Joel, DiMaggio Elizabeth, Ward Kimberly, Chau Jamie, Otteni Christopher, Kalos Denise, Ali Johannes, Hall MacLean S, Beatty Matthew, Klinkova Olga V, Alomar Mohammed E, Gaskill Eric E, Gonzalez Rebecca M, Bailey Hanna, Yu Michael, Tran Nam, Rodriguez-Alfonso Lianicet, Vieira Ella, Adams Karla, Jain Michael, Locke Frederick L, Baldonado Jobelle, Perez Matthew C, Mullinax John, Zager Jonathan S, Gonzalez Ricardo, Sondak Vernon K, Markowitz Joseph, Brohl Andrew S, Eroglu Zeynep, Tarhini Ahmad A, Khushalani Nikhil I, Mulé James J, Sarnaik Amod A, Pilon-Thomas Shari. Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients.. Transplantation and cellular therapy. 2025. DOI: 10.1016/j.jtct.2025.12.009.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.